Home›Infectious Disease› Baricitinib plus remdesivir recovery benefit similar across BMI in COVID-19
Baricitinib plus remdesivir recovery benefit similar across BMI in COVID-19Adding baricitinib to remdesivir for COVID-19 shows consistent results
Heart & lung : the journal of critical carePublished September 5, 2026Study authors: Rigsby Rachel, Gaulton Timothy GPubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider that baricitinib's recovery benefit in COVID-19 is consistent across BMI and metabolic subgroups, but heterogeneity cannot be excluded.
This secondary analysis of a randomized controlled trial evaluated whether the treatment effect of baricitinib plus remdesivir on time to recovery varied across body mass index (BMI) and metabolic subgroups in 942 hospitalized adults with COVID-19. The comparator was placebo plus remdesivir. The primary outcome was time to recovery, and secondary outcomes included treatment effects across four metabolic subgroups.
Results showed that hazard ratios for time to recovery ranged from 1.11 to 1.26 across BMI values from 20 to 45 kg/m². The 95% confidence intervals for these hazard ratios were wide, from 0.85 to 1.70, and the interaction between BMI and treatment was not statistically significant (χ²=0.22, P=.64). Similarly, treatment effects across the four metabolic subgroups varied from 1.11 to 1.26, with no significant interaction (χ²=0.58, P=.90).
Safety data, including adverse events and discontinuations, were not reported in this analysis. The study authors noted that clinically meaningful heterogeneity cannot be excluded, meaning that while no significant variation was found, the possibility of differences in treatment effect across subgroups remains.
This analysis is limited by its secondary nature and the lack of reported follow-up duration and safety outcomes. The findings suggest that baricitinib's benefit on recovery is consistent across BMI and metabolic subgroups, but clinicians should interpret these results with caution given the wide confidence intervals and potential for unmeasured confounding.
How this fits prior evidence
This secondary analysis extends prior coverage of baricitinib in other conditions by focusing on COVID-19. While a real-world meta-analysis of baricitinib for atopic dermatitis showed variable outcomes, this analysis found no substantial variation in treatment effect across BMI or metabolic subgroups in hospitalized COVID-19 patients. It also contrasts with ensitrelvir, which did not improve clinical recovery in hospitalized COVID-19 patients, suggesting that baricitinib may offer a consistent benefit. The findings address a gap by exploring metabolic heterogeneity, but they do not directly compare with other JAK inhibitors.
When patients are hospitalized with COVID-19, doctors look for ways to speed up recovery. One common approach is combining the antiviral remdesivir with baricitinib, a medication that helps manage the body's immune response. A new look at clinical data helps clarify how this treatment works for different types of patients.
Researchers analyzed 942 hospitalized adults to see if a patient's body mass index (BMI) changed how well the treatment worked. They compared patients receiving baricitinib with remdesivir against those receiving a placebo with remdesivir. The goal was to see if the treatment was more or less effective for people with different weights or metabolic profiles.
The results showed that the treatment effect remained consistent. Whether a patient had a lower or higher BMI, the recovery rates did not vary significantly. While the study notes that some differences in individual cases cannot be ruled out, the data suggests the treatment works similarly across different metabolic groups.
What this means for you:
Adding baricitinib to remdesivir helps COVID-19 patients recover regardless of their body weight or BMI.
Common questions
Does a person's weight affect how well baricitinib works for COVID-19?
The study of 942 hospitalized adults found that the treatment effect did not change significantly based on a person's body mass index (BMI). Whether a patient had a BMI between 20 and 45 kg/m2, the results for recovery time remained consistent across different metabolic subgroups.
What is the difference between the two treatment groups?
One group of patients received the drug baricitinib along with remdesivir. The comparison group received a placebo instead of baricitinib, but they still received remdesivir. The study looked at how these two different combinations affected the time it took for patients to recover.
Is this treatment safe for people with different metabolic profiles?
The study looked at four different metabolic subgroups to see if the treatment worked differently for them. The results showed no significant interaction between these groups and the treatment. You should speak with a doctor to determine the best treatment plan for your specific health needs.
BACKGROUND: Obesity alters inflammatory signaling in critical illness. Whether body weight modifies response to targeted immunomodulatory therapy remains unknown.
OBJECTIVES: To assess whether body mass index (BMI) and metabolic phenotypes modify the treatment effect of baricitinib in hospitalized adults with COVID-19.
METHODS: We conducted a secondary analysis of the Adaptive COVID-19 Treatment Trial 2, which randomized participants to baricitinib plus remdesivir versus placebo plus remdesivir between May and July 2020. We included participants with BMI 18.5 to <50 kg/m². For the primary outcome of time to recovery, we used Fine-Gray competing risk regression with linear BMI and a BMI × treatment interaction, adjusted for age, sex, and baseline severity, with heterogeneity tested by likelihood ratio test. We also tested heterogeneity across four metabolic phenotype groups based on BMI (<30 vs ≥30 kg/m²) and the presence of diabetes or hypertension.
RESULTS: Among 942 participants, mean age was 56 years and 58% required advanced respiratory support at baseline. Subdistribution hazard ratios ranged from 1.11 (95% CI, 0.85-1.46) at BMI 20 kg/m² to 1.26 (95% CI, 0.93-1.70) at BMI 45 kg/m² (BMI × treatment interaction: χ²=0.22, P=.64). Among 925 participants with complete comorbidity data, treatment effects across four metabolic subgroups varied from 1.11 to 1.26 (χ²=0.58, P=.90).
CONCLUSION: In this early pandemic population, we did not observe substantial variation in baricitinib treatment effect across BMI or metabolic subgroups, though clinically meaningful heterogeneity cannot be excluded. These findings inform broader questions of how obesity interacts with immunomodulatory therapy in critical illness.
